XEPI
Clinical safety rating: caution
Comprehensive clinical and safety monograph for XEPI (XEPI).
Ozenoxacin is a topical fluoroquinolone antibiotic that inhibits bacterial DNA replication by binding to bacterial DNA gyrase (topoisomerase II) and topoisomerase IV, leading to cell death.
| Metabolism | Systemic absorption is minimal; metabolism in systemic circulation is negligible. If absorbed, it is not extensively metabolized. |
| Excretion | Approximately 80% eliminated renally as unchanged drug via glomerular filtration and tubular secretion. Approximately 20% eliminated in feces via biliary excretion. |
| Half-life | Terminal elimination half-life is approximately 8 hours in patients with normal renal function (creatinine clearance ≥90 mL/min). In moderate renal impairment (CrCl 30-59 mL/min), half-life extends to about 15 hours. |
| Protein binding | Approximately 30% bound to plasma proteins, primarily albumin. |
| Volume of Distribution | Volume of distribution is approximately 0.2-0.3 L/kg, indicating primarily extracellular fluid distribution with limited tissue penetration. |
| Bioavailability | Intravenous: 100% bioavailable. Oral bioavailability not applicable as drug is only administered intravenously. |
| Onset of Action | Intravenous administration: Clinical effect (bactericidal activity) within 30 minutes; tissue distribution rapid. |
| Duration of Action | Duration of bactericidal activity approximately 12-24 hours, supporting once-daily dosing in most infections. Prolonged in renal impairment. |
| Molecular Weight | 478.54 |
Topical: Apply a pea-sized amount to the affected area twice daily. For moderate to severe plaque psoriasis, initiate treatment with clobetasol propionate spray 0.05% applied twice weekly (Sunday and Thursday) to the scalp and/or body lesions. For plaque psoriasis under occlusion or on limited areas, clobetasol propionate foam 0.05% applied twice daily. For scalp psoriasis, clobetasol propionate shampoo 0.05% applied once daily to the dry scalp, left for 15 minutes, then rinsed. For steroid-responsive dermatoses, clobetasol propionate ointment, cream, or lotion 0.05% applied sparingly to the affected area twice daily (morning and night) for up to 2 weeks; re-evaluate if no improvement. Maximum dose: 50 g/week of 0.05% preparation; for scalp applications, 50 mL/week.
| Dosage form | CREAM |
| Renal impairment | No dosage adjustment is required in patients with renal impairment as topical absorption is minimal. Systemic toxicity is unlikely, but caution is advised in severe renal impairment due to potential accumulation of excipients. For oral formulations (not applicable), no data available. |
| Liver impairment | No dosage adjustment is required in patients with hepatic impairment based on low systemic absorption. However, in severe hepatic impairment (Child-Pugh C), systemic corticosteroid effects may be potentiated; use with caution and limit application area. For oral formulations (not applicable), no data available. |
| Pediatric use | Safety and efficacy in pediatric patients have not been established. Use is not recommended for children under 12 years of age due to higher risk of hypothalamic-pituitary-adrenal axis suppression. For children 12-17 years, apply the same dose as adults but limit treatment to 2 weeks; do not use under occlusion; avoid face, axillae, and groin. Maximum duration: 2 consecutive weeks. |
| 1st trimester | Contraindicated due to risk of fetal malformations based on animal studies and limited human data. |
| 2nd trimester | Contraindicated due to risks of fetal hypotension, tachycardia, and potential hypoxia. |
| 3rd trimester | Contraindicated due to risks of fetal hypotension, tachycardia, and potential hypoxia during labor. |
Clinical note
Comprehensive clinical and safety monograph for XEPI (XEPI).
| Placental transfer | Based on molecular weight and pharmacokinetics, placental transfer is expected; animal studies confirm fetal exposure. |
| Breastfeeding | Excretion into human milk is unknown. Given the potential for serious adverse reactions in nursing infants, breastfeeding is not recommended during treatment. |
| Lactation Rating |
■ FDA Black Box Warning
None.
| Serious Effects |
Hypersensitivity to the active substance or any excipientConcurrent administration with xanthine derivativesSevere hypertensionHypovolemiaCoronary artery diseaseHistory of stroke or transient ischemic attack
| Precautions | Hypersensitivity reactions including anaphylaxis have been reported. Discontinue if rash or other allergic symptoms occur. Avoid prolonged use as it may result in overgrowth of non-susceptible organisms including fungi. For external use only; not for ophthalmic, oral, or intravaginal use. |
| Food/Dietary | No clinically significant food interactions. XEPI is applied topically and not absorbed systemically; dietary restrictions are not required. |
Loading safety data…
| Geriatric use | No specific dose adjustment is needed, but elderly patients may have increased susceptibility to topical corticosteroid adverse effects due to age-related skin thinning. Use the lowest effective dose for the shortest duration. Monitor for skin atrophy, telangiectasias, and systemic absorption. Avoid use on large areas or under occlusion. Apply sparingly and discontinue if irritation occurs. |
| L5 - Contraindicated |
| Teratogenic Risk | XEPI (cefepime, enmetazobactam) is classified as Pregnancy Category B based on animal studies. There are no adequate and well-controlled studies in pregnant women. For trimester 1, 2, and 3, the potential risk to the fetus is considered low based on animal data, but the drug should only be used if clearly needed. No specific teratogenic patterns have been identified. |
| Fetal Monitoring | Monitor for maternal hypersensitivity reactions, diarrhea (C. difficile colitis), and changes in renal function. Fetal monitoring is not specifically required, but standard obstetric monitoring is recommended during treatment of maternal infections. For prolonged therapy, monitor for signs of neutropenia or superinfection. |
| Fertility Effects | Animal studies with cefepime and enmetazobactam have not shown adverse effects on fertility or reproductive performance. No human data are available. The potential for reversible impairment of spermatogenesis is not evaluated, but based on beta-lactam class effects, impact on fertility is unlikely. |
| Clinical Pearls |
| XEPI (ozenoxacin) is a topical antibiotic for impetigo. Apply a thin layer to affected area twice daily for 5 days. No systemic absorption; safe for children 2 months and older. Avoid use on large areas of damaged skin or in patients with known hypersensitivity to quinolones. Monitor for local irritation or allergic contact dermatitis. |
| Patient Advice | Apply a thin layer of the cream to the infected skin area exactly as prescribed. · Wash hands before and after applying the medication. · Do not cover the treated area with bandages or dressings unless instructed by your doctor. · Use for the full prescribed duration, even if symptoms improve, to prevent recurrence. · Avoid sharing towels, clothing, or bedding to prevent spread of infection. · Notify your doctor if skin irritation, rash, or signs of allergy develop. |